Pharmacokinetics of marbofloxacin in lactating cows after repeated intramuscular administrations and pharmacodynamics against mastitis isolated strains

Journal of Dairy Science

Volumn 87, Issue 1, 2004, Pages 202-211

  Schneider, M ^a   Valle M ^a   Woehrle F ^a   Boisrame B ^a  

^a Vétoquinol Laboratory   (France)

Author keywords

Marbofloxacin; Pharmacodynamics; Pharmacokinetics; Surrogate marker

Indexed keywords

BACTERIA (MICROORGANISMS); BOS TAURUS; ESCHERICHIA COLI; STAPHYLOCOCCUS AUREUS;

MARBOFLOXACIN; QUINOLONE DERIVATIVE;

ANIMAL; ARTICLE; CATTLE; CATTLE DISEASE; DRUG EFFECT; ESCHERICHIA COLI; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAMUSCULAR DRUG ADMINISTRATION; KINETICS; LACTATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MILK; STAPHYLOCOCCUS AUREUS;

ANIMALS; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESCHERICHIA COLI; FEMALE; FLUOROQUINOLONES; INJECTIONS, INTRAMUSCULAR; KINETICS; LACTATION; MASTITIS, BOVINE; MICROBIAL SENSITIVITY TESTS; MILK; QUINOLONES; STAPHYLOCOCCUS AUREUS;

EID: 1642485830     PISSN: 00220302     EISSN: None     Source Type: Journal    
DOI: 10.3168/jds.S0022-0302(04)73159-8     Document Type: Article

References (34)

1. Bousquet-Melou, A., S. Bernard, M. Schneider, and P. L. Toutain. 2002. Pharmacokinetics of marbofloxacin in horses. Equine Vet. J. 34:366-372.
2. Carretero, M., C. Rodriguez, M. I. San Andrés, P. Forés, J. J. de Lucas, J. Nieto, S. Waxmann, M. D. San Andrés, and F. González. 2002. Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration. Equine Vet. J. 34:360-365.
3. Cruz, A. D., G. C. M. Batista, J. R. Modolo, A. F. Gottschalk, and C. A. M. Lopes. 1998. Antimicrobial activity of danofloxacin and seven other drugs against Staphylococcus aureus from mastitis. Arquivo Brasileiro de Medicina Veterinaria V50 No. 4:369-373.
4. DANMAP. 2000:2001. Consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmak. Ed. Danish Veterinary Laboratory, Copenhagen, Denmark.
5. DANMAP. 2000:2001. Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmak. Ed. Danish Veterinary Laboratory, Copenhagen, Denmark.
6. De Oliveira, A. P., J. L. Watts, S. A. Salmon, and F. M. Aarestrup. 2000. Antimicrobial susceptibility of Staphylococcus aureus isolated from bovine mastitis in Europe and the United States. J. Dairy Sci. 83:855-862.
7. Fang, W., and S. Pyörälä. 1996. Mastitis-causing Escherichia coli: Serum sensitivity and susceptibility to selected antibacterials in milk. J. Dairy Sci. 79:76-82.
8. Gianneechini, R. E., C. Concha, and A. Franklin. 2002. Antimicrobial susceptibility of udder pathogens isolated from dairy herds in the west littoral region of Uruguay. Acta Vet. Scand. 43:31-41.
9. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics. Marcel Dekker Inc, New York, NY.
10. Grandemange, E., and J. L. Davot. 2002. Field evaluation of the efficacy of marbofloxacin in the treatment of acute mastitis due to Gram-negative bacteria in the dairy cow. Cattle Practice 10:57-62.
11. Hoeben, D., E. Monfardini, C. Burvenich, and J. Hamann 2000. Treatment of acute Escherichia coli mastitis in cows with enrofloxacin: Effect on clinical signs and chemiluminescence of circulating neutrophils. J. Dairy Res. 67:485-502.
12. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin. Pharmacokinetics 28:143-160.
13. Kaartinen, L., M. Salonen, L. Älli, and S. Pyörälä. 1995. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J. Vet. Pharmacol. Therap. 18:357-362.
14. Lefebvre, H. P., M. Schneider, V. Dupouy, V. Laroute, G. Costes, L. Delesalle, and P. L. Toutain. 1998. Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog. J. Vet. Pharmacol. Therap. 21:453-461.
15. NCCLS, Document M26-A. 1999. Methods for determining bactericidal activity of antimicrobial agents.
16. NCCLS, Document M31-A. 1999. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals.
17. NCCLS, Document M37-A. 1999. Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobials agents.
18. Petracca, K., J. L. Riond, T. Graser, and M. Wanner. 1993. Pharmacokinetics of the gyrase inhibitor marbofloxacin: Influence of pregnancy and lactation in sows. J. Vet. Med. 40:73-79.
19. Pickerill, K. E., J. A. Paladino, and J. J. Schentag. 2000. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 20:417-428.
20. Rantala, M., L. Kaartinen, E. Välimäki, M. Stryrman, M. Hiekkaranta, A. Niemi, L. Saari, and S. Pyörälä. 2002. Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. J. Vet. Pharmacol. Therap. 25:251-258.
21. Ross, D. L., and C. M. Riley 1994. Dissociation and complexation of the fluoroquinolone antimicrobials-an update. J. Pharm. Biomed. Anal. 12:1325-1331.
22. Salmon, S. A., J. L. Watts, F. M. Aarestrup, J. W. Pankey, and R. J. Yancey, Jr. 1998. Minimum inhibitory concentrations for selected antimicrobial agents against organisms isolated from mammary glands of dairy heifers in New Zealand and Denmark. J. Dairy Sci. 81:570-580.
23. Schentag, J. J. 1999. Antimicrobial action and pharmackinetics/ pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance. J. Chemother. 11:426-439.
24. Schentag, J. J., K. K. Gilliland, and J. A. Paladino. 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32:S39-S46.
25. Schlegelva, J., V. Babak, E. Klimova, J. Lukasova, P. Navratilova, A. Sustackova, I. Sediva, and D. Rysanek. 2002. Prevalence and resistance to anti-microbial drugs in selected microbial species isolated from milk samples. J. Vet. Med. 49:216-225.
26. Schneider, M., V. Thomas, B. Boisramé, and J. Deleforge. 1996. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J. Vet. Pharmacol. Therap. 19:56-61.
27. Shem-Tov, M., G. Ziv, A. Glickman, and A. Saran. 1997. Pharmacokinetics and penetration of marbofloxacin from blood into the milk of cows and ewes. J. Vet. Med. 44:511-519.
28. Shem-Tov, M., O. Rav-Hon, G. Ziv, E. Lavi, A. Glickman, and A. Saran. 1998. Pharmacokinetics and penetration of danofloxacin from the blood into the milk of cows. J. Vet. Pharmacol. Therap. 21:209-213.
29. Spreng, M., J. Deleforge, V. Thomas, B. Boisramé, and H. Drugeon. 1995. Antibacterial activity of marbofloxacin, a new fluoroquinolone for veterinary use against canine and feline isolates. J. Vet. Pharmacol. Therap. 18:284-289.
30. Thomas, A., C. Nicolas, I. Dizier, J. Mainil, and A. Linden. 2002. In vitro antimicrobial susceptibility of mycoplasma bovis strains isolated from Belgian cattle. Proceedings from the XXII World Buiatrics Congress 2002, Hannover, Germany.
31. Thomas, V., J. Deleforge, and B. Boisramé. Pharmacokinetics of marbofloxacin in pre-ruminant and ruminant cattle. 1994. Pages 60-61 in Proc. 6th Congr. Europ. Assoc. Vet. Pharmacol. Toxicol. Blackwell Science Ltd., Edinburgh.
32. Von Walser, K., B. Gandorfer, A. Steinberg, E. Treiting, and T. Winter. 1993. Untersuchungen zur antibakteriellen aktivität und pharmakokinetik von enrofloxacin (Baytril®) bei der laktierenden kuh. Tierärztl. Umschau. 48:414-419.
33. Watts, J. L., S. A. Salmon, R. J. Yancey, Jr., S. C. Nickerson, L. J. Weaver, C. Holmberg, J. W. Pankey, and L. K. Fox. 1995. Antimicrobial susceptibility of microorganisms isolated from the mammary glands of dairy heifers. J. Dairy Sci. 78:1637-1648.
34. Waxman, S., C. Rodriguez, F. Gonzales, M. L. De Vicente, M. I. San Andres, and M. D. San Andres. 2001. Pharmacokinetic behaviour of marbofloxacin after intravenous and intramuscular administrations in adult goats. J. Vet. Pharmacol. Therapeutics 24:375-378.